TD Cowen raised the firm’s price target on Krystal Biotech to $160 from $130 and keeps an Outperform rating on the shares. The firm said Krystal Biotech is a gene therapy company whose lead therapy, Vyjuvek for dystrophic epidermolysis bullosa (DEB), was recently approved. The company’s updated estimation of $750M+ in peak sales worldwide. We believe investors underappreciate the market size and commercial strength of Vyjuvek’s imminent launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech to Present at Upcoming Investor Conferences
- Biotech Alert: Searches spiking for these stocks today
- Krystal Biotech Announces $160 Million Private Placement Equity Financing
- Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
- Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights